Nearly 100 years after the discovery of insulin, over 70% of patients with type 1 diabetes (T1D) continue to have unsatisfactory glycaemic control putting them at risk of long-term complications.1 Tragically, death rates among adolescents have not improved in the last few decades (1968–2009).2 Despite major advances in closed loop insulin pump therapy, much of the morbidity arises from young people failing to engage with complex therapies. Here, INS is linked to type 1 diabetes mellitus.